COMMUNIQUÉS West-GlobeNewswire

XBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active
15/06/2026
La demande d’IND pour l’étude V-SPINE a fait l’objet d’un examen de 30 jours par la FDA sans suspension clinique, ouvrant ainsi la voie au recrutement de patients aux États-Unis AUSTIN, Texas, 15 juin 2026 (GLOBE [...]
ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea
15/06/2026
Integration supports remote patient monitoring and value-based care SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“ [...]
Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO
15/06/2026
Seasoned biopharma executive with extensive experience building and leading organizations and supporting therapeutic pipeline programs in psychiatry MORRISTOWN, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Reunion [...]
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
15/06/2026
--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15, 2026 (GLOBE [...]
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
15/06/2026
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function Raanana, Israel [...]
Immuneering Appoints Andrew Gengos as Chief Financial Officer
15/06/2026
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering [...]
Novo Nordisk A/S - share repurchase programme
15/06/2026
Bagsværd, Denmark, 15 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
15/06/2026
-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are [...]
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
15/06/2026
The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S. FESILTY complements Grifols’ bleeding [...]
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
15/06/2026
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today [...]
Cannabix Technologies Announces Deployment of Marijuana Breath Test (MBT) with Major Industrial Operator in Quebec
15/06/2026
VANCOUVER, British Columbia, June 15, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
15/06/2026
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX’s platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including [...]
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
15/06/2026
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society’s annual meeting. The poster [...]
10 Barrel Brewing and Pub Beer Kick Off Pacific Northwest Summer of Soccer Celebration
15/06/2026
As global soccer fever builds, 10 Barrel Brewing and Pub Beer are bringing fans together across the Pacific Northwest with watch parties, game-day limited-edition merch and activations, sweepstakes and more BEND, Ore., [...]
Le KFSH met en avant la transformation des prestataires grâce à un impact opérationnel mesurable au HLTH Europe 2026
15/06/2026
AMSTERDAM, 15 juin 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) véhicule un message de transformation pratique des prestataires lors de sa participation au HLTH Europe 2026, [...]
Aerska Strengthens Board with Appointments of Uli Stilz and Itziar Canamasas
15/06/2026
DUBLIN and LONDON, 15 June 2026 -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announces the appointment of Itziar Canamasas and Uli Stilz to the [...]
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
15/06/2026
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, [...]
Sparrow Pharmaceuticals Announces Interim CAPTAIN-T2D Data Validating High Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes
15/06/2026
More than 75% of patients screened show elevated cortisol level associated with increased prevalence of cardiovascular disease Inadequate glycemic control despite incretin mimetic use and concomitant hypertension were [...]
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
15/06/2026
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML 32 AML patients dosed across 40 mg, 80 mg, 120 mg and 160 mg TUS with TUS+ [...]

Pages